Hope on the Horizon in Ovarian Cancer
HTML-код
- Опубликовано: 29 сен 2024
- #93! Opening our 2024 series of Connect Ovar Coffee ☕️ with our Advisory Board Member Dr. Marta Crispens, Director of Gynecologic Oncology, Vanderbilt University Medical Center, to Talk About Hope on the Horizon in Ovarian Cancer.
Let's Learn. Let's #ConnectOvarCoffee ☕️ !
![DDG & G Herbo - Nosey [Official Video]](http://i.ytimg.com/vi/I9Ra0Zc2NlQ/mqdefault.jpg)
Advancements/breakthroughs in clear cell?
We are going to focus one episode on clear cell/rare ovarian cancers soon - please stay tuned. Thank you for watching 🙏🏼. Keep Ovarcoming! 💙
Here is some information on a new trial on clear cell that was shared with us by the Principal Investigator Dr. Amir Jazaeri: classic.clinicaltrials.gov/ct2/show/NCT06065462. Thank you! 🙏
What would be helpful is for the FDA to approve his previous successful trial using single and combo immunotherapy. The response rate and duration of response is much better than anything else - especially since there are zero treatments for clear cell ovarian. They impose drugs for a completely different cancer molecularly with Dr. Crispin says here needs a different treatment. The therapies for ovarian cancer do not apply to clear cell - she says so here. But we are forced to take them as the only "standard of care" for them, knowing full well they will die and the therapy will not work, because it is teated and developed for a completely different cancer, molecularly.. Ovarian clear cell has more in common with REnal and Endometrial clear cell.. One trial in Texas from the wonderful Dr. Jazeari is not enough. There should be trials using his findings re immunotherapy that ends in an approved treatment. We currentlly have zero. (unless we have a certain mutation?) For oncologists to knowing force treatments they know aren't going to work is so wrong.. There needs to be a Clear Cell advocacy group. I admire Ovarcome for their advocacy and education because otherwise the NCCN et al are not encouraging screening and that's why we have an 85% death rate. @@Ovarcome
If you have any questions as we go along, please put in the comments section - chat seems to disappear!
Does olaparib tablet taken after chemotherapy help to keep cancer away in patients with brca mutated genes, successfully
Thank you so much for some really helpful, down to earth advice. Very interesting and informative. I like the final point made about grace and acceptance. Thank you.
Thank you for your kind feedback 🙏🏼. Please share the wonderful insights provided by Dr. Crispens with anyone who may benefit. Thank you for watching! Keep Ovarcoming! 💙
Why is pfs relevant to someone who has responded and been on treatment for 3 years?
We will send this question over to Dr. Crispens and follow up here if she provided a response. Thank you for watching! Keep Ovarcoming! 💙
What was the drug Dr Crispens mentioned at the end of her talk that one of her patients was using who was platinum resistant.
we think it was Elahere, the Antibody Drug Conjugate - you can also now watch the video on demand and go back to that particular snapshot where Dr. Crispens spoke about this drug. Thank you so much for watching. Keep Ovarcoming! 💙🙏🏼
I did go back and listen a few times and could never make out what she said. It is also not in the written transcript. It was a drug used if you are platinum resistant.
@@laraineseifer3454 we listened again to get the answer for you - it was as we mentioned in our first comment. It is called ELAHERE - it is an ADC for platinum resistant ovarian cancer. Details here: www.elahere.com/. Thank you - keep Ovarcoming! 💙
Thank you for the information and support!!
Thank you so much for watching and for your kind feedback 🙏🏼. Keep Ovarcoming! 💙
I can't figure out how to attach things. The name of the article about the trial which has charts for the below 25 saturation is "Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha
(FRα)-targeting antibody-drug conjugate (ADC), in combination with
bevacizumab in patients with platinum-resistant ovarian cancer" in Gynecological Oncology.
I also belong to the Elahere for platinum resistant (and now I think they added platinum sensitive) facebook group , can't upload pdfs there tho. only jpgs I think..
My mother, 70 years has just finished treatment with chemotherapy for ovarian cancer, has been asked to take daily 4 tablets of olaparib tablet 150 mg for next two years, as she is brca (HRD) positive. Hope she will stay in remission at least next two years and more, no recurrence in any sites 😢😢
@@navbharat1443 thank you for sharing. Sending much love and best wishes to your Mom as she Ovarcomes, and to you as well. Thank you for watching! Keep Ovarcoming! 💙
There was some misinformation about mirv . In a study of mirv and Avastin that allowed low FRA the low FRA who responded did 3x better in os than high FRA. The difference is in response rate.
I'm curious, I'd like to read that study. Would you be able to send the link please?
@@NurseQuipy I think I have a chart of their results but maybe not on this phone. I'll look . I'm afraid of not being able to find my way back to your question! It's not on my phone, I'll have to look on my computer . The OS for low FRA was 18 months - there may have been complete response. Low number of these patients but it makes sense in a way because high FRA = aggressive cancer- so if elahere hits the target of low FRA it makes sense they would do better. The only benefit of high FRA is it's easier for drug to find these tumors, so there is a higher response rate. It has nothing to do with how effective it is.
Thank you Margaret - was the information provided by Dr. Crispens?
Please send the article.